Through the agreement, Orthofix has the rights to pursue FDA approvals and commercialization of Italy-based Igea’s platform of orthopedic products. Orthofix will market the products, which will expand its bone growth therapies portfolio of pulsed electromagnetic field (PEMF) products with other indications for low-intensity pulsed ultrasound (LIPUS) and capacitive coupling (CC) for fracture management.
“Orthofix is the U.S. market leader with our PEMF technology bone growth stimulation systems indicated for post-operative spinal fusions and treating bone fractures that have not healed after surgery, and Igea is the European market and technology leader for bone and joint stimulation,” Orthofix president and CEO Jon Serbousek said in a news release. “Combined, these portfolios will enable us to offer physicians and patients additional treatment solutions for fracture management and complement our pursuit of new indications for managing soft tissue and joint health such as our ongoing rotator cuff repair IDE clinical study.”
Igea develops bone and joint cartilage stimulation systems. More than 20,000 patients outside of the U.S. are treated with its products every year, according to the company.
“As a company with a long history of treating patients in Europe, we are excited to enter into this agreement that will expand the availability of our bone and joint cartilage systems to patients in the U.S.,” Igea president and founder Ruggero Cadossi said. “Aligning with Orthofix’s expertise and distribution in the stimulation market enables us to provide even more physicians access to our innovative products to improve patient outcomes.”